196.56 USD
+3.59 (+1.86%)
196.56 USD
0 (0%)
Taking everything into account, LGND scores 6 out of 10 in our fundamental rating. LGND was compared to 191 industry peers in the Pharmaceuticals industry. While LGND has a great profitability rating, there are some minor concerns on its financial health. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make LGND suitable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year LGND was profitable.
- In the past year LGND had a positive cash flow from operations.
- In multiple years LGND reported negative net income over the last 5 years.
- LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- LGND's Return On Assets of 3.29% is amongst the best of the industry. LGND outperforms 83.25% of its industry peers.
- LGND has a Return On Equity of 5.11%. This is amongst the best in the industry. LGND outperforms 83.25% of its industry peers.
- LGND has a Return On Invested Capital of 1.58%. This is in the better half of the industry: LGND outperforms 78.53% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for LGND is significantly below the industry average of 12.84%.
- The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
- LGND's Profit Margin of 19.34% is amongst the best of the industry. LGND outperforms 90.58% of its industry peers.
- Looking at the Operating Margin, with a value of 11.48%, LGND belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
- LGND's Operating Margin has declined in the last couple of years.
- The Gross Margin of LGND (94.27%) is better than 96.34% of its industry peers.
- In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LGND is destroying value.
- The number of shares outstanding for LGND has been increased compared to 1 year ago.
- The number of shares outstanding for LGND has been increased compared to 5 years ago.
- Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
- LGND has an Altman-Z score of 5.70. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.70, LGND is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
- LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
- The Debt to FCF ratio of LGND (14.48) is better than 77.49% of its industry peers.
- LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of LGND (0.47) is worse than 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.7 |
ROIC/WACC0.17
WACC9.38%
2.3 Liquidity
- LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- LGND has a Current ratio of 24.69. This is amongst the best in the industry. LGND outperforms 93.72% of its industry peers.
- A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
- LGND has a Quick ratio of 24.30. This is amongst the best in the industry. LGND outperforms 92.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.26% over the past year.
- Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
- Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 64.83%.
- Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
- LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.28% yearly.
- The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 26.96 indicates a quite expensive valuation of LGND.
- Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 78.01% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.94, LGND is valued at the same level.
- LGND is valuated rather expensively with a Price/Forward Earnings ratio of 23.36.
- Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than 75.92% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, LGND is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.96 | ||
| Fwd PE | 23.36 |
4.2 Price Multiples
- 76.96% of the companies in the same industry are more expensive than LGND, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than 75.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 125.76 | ||
| EV/EBITDA | 48.44 |
4.3 Compensation for Growth
- LGND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- LGND has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as LGND's earnings are expected to grow with 19.77% in the coming years.
PEG (NY)0.88
PEG (5Y)2.01
EPS Next 2Y21.4%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
- LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
196.56
+3.59 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners106.73%
Inst Owner Change1%
Ins Owners1.62%
Ins Owner Change-1.3%
Market Cap3.87B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (26.33%)
Short Float %6.48%
Short Ratio5.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)2.5%
PT rev (3m)32.94%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)-23.57%
EPS NY rev (1m)-3.25%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-10.47%
Revenue NY rev (1m)-5.71%
Revenue NY rev (3m)12.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.96 | ||
| Fwd PE | 23.36 | ||
| P/S | 15.4 | ||
| P/FCF | 125.76 | ||
| P/OCF | 121.21 | ||
| P/B | 4.07 | ||
| P/tB | 9.46 | ||
| EV/EBITDA | 48.44 |
EPS(TTM)7.29
EY3.71%
EPS(NY)8.41
Fwd EY4.28%
FCF(TTM)1.56
FCFY0.8%
OCF(TTM)1.62
OCFY0.83%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.88
PEG (5Y)2.01
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.7 |
F-Score5
WACC9.38%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.